Cyclerion Therapeutics Q2 FY26: revenue $0; diluted EPS −$0.41

Key figures from this report

These are the numbers Cyclerion Therapeutics reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$0−100% from $93K in Q2 FY2510-Q income statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
2. Net income−$1.8MAgainst −$324K in Q2 FY2510-Q income statement, on EDGAR
3. Diluted EPS−$0.41Against −$0.11 in Q2 FY2510-Q income statement, on EDGAR
4. Cash and cash equivalents$1.4M−54% from $3.0M in Q2 FY2510-Q balance sheet, on EDGAR
5. Cash from operations−$1.4MAgainst −$503K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables